Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

PURPOSE: Crizotinib is an oral kinase inhibitor approved for the treatment of ALK-rearranged non–small-cell lung cancer (NSCLC). The clinical benefits of crizotinib in patients with brain metastases have not been previously studied. PATIENTS AND METHODS: Patients with advanced ALK-rearranged NSCLC e...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Costa, Daniel B., Shaw, Alice T., Ou, Sai-Hong I., Solomon, Benjamin J., Riely, Gregory J., Ahn, Myung-Ju, Zhou, Caicun, Shreeve, S. Martin, Selaru, Paulina, Polli, Anna, Schnell, Patrick, Wilner, Keith D., Wiltshire, Robin, Camidge, D. Ross, Crinò, Lucio
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2015
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4451171/
https://ncbi.nlm.nih.gov/pubmed/25624436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.59.0539
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky